



December 23, 2020

PeptiDream Inc.

<http://www.peptidream.com>

(Ticker Code: 4587 TSE First Section)

## **PeptiDream Announces Licensing of Peptide Discovery Platform System (PDPS) Technology to Janssen**

KANAGAWA, JAPAN – December 23<sup>rd</sup>, 2020 – PeptiDream Inc., public Kanagawa-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587) announced today that it has entered into a License and Technology Transfer Agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ), to grant a non-exclusive license of PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology to Janssen and its affiliates. The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, PeptiDream will receive technology access payments and is eligible to receive development milestones and royalties on certain products that are originated under the agreement.

PeptiDream will continue to work with Janssen to identify macrocyclic/constrained peptides against Janssen targets of interest and to optimize candidates into therapeutic products using PeptiDream’s PDPS technology, under a prior agreement entered into between PeptiDream and Janssen Pharmaceuticals, Inc. in April 2017.

### **[Comment from Patrick C. Reid, CEO of PeptiDream Inc.]**

*“We are delighted to announce the technology license with Janssen. Our R&D collaboration, which started in April 2017, has already made incredible progress, with two development milestones already achieved, through which we have been able to demonstrate the power of our proprietary PDPS technology in both hit identification and also in subsequent optimization of those candidates into potential clinical candidates. We continue to gain experience and knowledge in turning PDPS identified peptide candidates into peptide therapeutics and/or small molecule therapeutics, efforts that are greatly accelerated with the information shared and learned across all our collaboration partners and programs.”*

**<About PeptiDream Inc.>**

PeptiDream Inc. is a public (Tokyo Stock Exchange 1<sup>st</sup> Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit <https://www.peptidream.com>.

**Enquiries:****PeptiDream Inc.**

Mie Yamazaki IR - (Kanagawa)

EMAIL: [m-yamazaki@peptidream.com](mailto:m-yamazaki@peptidream.com)